Atenolol Exposure as Risk for Adverse Metabolic Responses to Beta Blockers

Completed · Not applicable

Conditions studied: Hypertension

In brief

The researchers hypothesize that the impact of increasing systemic exposure to atenolol leads to increased risk for adverse metabolic effects from atenolol therapy in hypertension. This will be accomplished through a 24-hour pharmacokinetic (PK) study and oral glucose tolerance test in hypertensive patients taking chronic atenolol 100 mg daily.

Key facts

Study ID

NCT00607347

Run by

University of Florida

People needed

24

Starts

2008-02-01

Expected to finish

2009-06-01

Last updated by the study team

2011-09-20

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects from PEAR who are on atenolol 100 mg once daily will be invited to participate
• Other inclusion criteria from PEAR

You may not qualify if…

• Patients with BMI >35 kg/m2 will be excluded
• Other exclusion criteria from PEAR

Where it is running

• University of Florida — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.